Neoleukin Therapeutics Inc (NLTX)
3.53
-0.06
(-1.67%)
USD |
NASDAQ |
Dec 08, 13:50
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 33.17M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 75.16% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.4409 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.64% |
Profile
| Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. |
| URL | https://www.neoleukin.com |
| Investor Relations URL | http://investor.aqxpharma.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 29, 2024 (est.) |
| Last Earnings Release | Nov. 14, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. |
| URL | https://www.neoleukin.com |
| Investor Relations URL | http://investor.aqxpharma.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 29, 2024 (est.) |
| Last Earnings Release | Nov. 14, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |